Blue Jet Healthcare Posts Q2 EBITDA Of ₹119 Crore With 31.6% Margin

Market snapshot: Blue Jet Healthcare Limited announced its quarterly financial metrics, highlighted by a strong surge in core profitability. Operating earnings before interest, taxes, depreciation, and amortisation (EBITDA) reached ₹119 crore for the quarter, compared to ₹54.95 crore in the corresponding prior-year period.

Data Snapshot

• Q2 EBITDA reached ₹119 crore, compared to ₹54.95 crore in the year-ago period, representing an expansion of 116.56% YoY.
• Q2 EBITDA margin stood at 31.60%, compared to 33.21% in the prior-year period.

What's Changed

• Q2 EBITDA grew to ₹119 crore from ₹54.95 crore YoY.
• Q2 EBITDA margin compressed modestly by 161 basis points YoY to 31.60% from 33.21%.

Key Takeaways

• Substantial increase in operational EBITDA reflects scale-up in primary pharmaceutical and contrast media intermediate categories.
• Operational margins remain resilient above 31% despite minor sequential and annual margin adjustments.
• Fixed cost absorption driven by higher production volumes supported earnings expansion.

SAHI Perspective

Blue Jet Healthcare's performance underlines strong volume trajectory in its niche CDMO operations. While EBITDA margins moderated slightly by 161 basis points YoY to 31.60%, absolute operating profit more than doubled, demonstrating robust operating leverage.

Market Implications

The significant operational earnings expansion reflects healthy customer demand normalization and throughput across manufacturing blocks, supporting growth stability in the specialty pharma segment.

Trading Signals

Market Bias: Bullish

Strong core earnings trajectory with EBITDA doubling YoY to ₹119 crore (vs ₹54.95 crore) while retaining a healthy margin profile at 31.60%.

Overweight: Pharmaceuticals & Healthcare, CDMO & Active Pharmaceutical Ingredients

Trigger Factors:

• Capacity utilization and ramp-up in pharmaceutical intermediates
• Raw material pricing stability and operating efficiency
• Commercialization timelines for greenfield manufacturing units

Time Horizon: Near-term (0-3 months)

Industry Context

Specialty pharmaceutical intermediate manufacturers continue to benefit from global supply chain realignment and customer inventory normalization following prior cyclical adjustments.

Key Risks to Watch

• Fluctuations in key starting material costs affecting gross margins
• Foreign currency exchange rate volatility on export revenues

Recent Developments

Brokerage insights highlighted an expected EBITDA margin trajectory around 25.5% to 26.5% for FY27 following 26.3% in Q1 FY27.

Closing Insight

Blue Jet Healthcare's operational results confirm robust execution and revenue conversion, maintaining high profitability metrics in contract manufacturing.

High Performance Trading with SAHI.